177Lu-JLT003 / Peking Union Medical College, Beijing Jiluntai Pharmaceutical - LARVOL DELTA

Integrin αvβ3-targeted radionuclide therapy with 177Lu-AB-3PRGD2 in multiple advanced metastatic solid tumors: A prospective, single-arm, single-center, investigator-initiated clinical trial. (ASCO 2026) - P1 | "Integrin αvβ3-targeted radionuclide therapy with ¹⁷⁷Lu-AB-3PRGD2 demonstrated promising efficacy in disease control and tumor response, and it was generally well tolerated in patients with advanced metastatic solid tumors. These findings justify further investigation in prospective, multicenter, randomized clinical trials."

Clinical • Metastases • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Kidney Cancer • Leukopenia • Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thrombocytopenia • Thyroid Gland Carcinoma

Initial Clinical Experience with 177Lu-AB-3PRGD2 Radioligand Therapy for Advanced-Stage Solid Tumors (SNMMI 2026) - "Integrin αvβ3-targeted radioligand therapy with 177Lu-AB-3PRGD2 was well tolerated, with a low rate of attributable adverse events. We observed signs of tumor response, but further studies are warranted to determine efficacy and the toxicity profile in a larger cohort."

Clinical • Metastases • Appendix Cancer • Biliary Cancer • Brain Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Genito-urinary Cancer • Glioma • Leukopenia • Lung Cancer • Oncology • Pancreatic Cancer • Rectal Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Thrombocytopenia • Thymus Cancer • Thyroid Gland Carcinoma

Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin α v β 3-positive tumors: A first-in-human study. (PubMed, Acta Pharm Sin B) - "This first-in-human study of 177Lu-AB-3PRGD2 treatment indicates its promising potential for targeted radionuclide therapy of integrin α v β 3-avid tumors. It merits further studies in more patients with escalating doses and multiple treatment courses."

Journal • P1 data • PK/PD data • Oncology

Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade. (PubMed, Eur J Nucl Med Mol Imaging) - "We developed a novel and long-acting radiotherapeutic agent 177Lu-AB-3PRGD2, and pioneered a strategy guided by PD-L1-targeted nuclear medicine imaging for the combination of TRT and ICB towards precision cancer therapy, optimizing the therapeutic efficacy and reducing the cost and potential toxicity risks. This strategy could also be adapted for clinical practice, combining conventional radiotherapy or chemotherapy with ICB to enhance therapeutic efficacy."

Checkpoint block • Checkpoint inhibition • IO biomarker • Journal • Oncology • CD8 • PD-L1

177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Peking Union Medical College Hospital | N=15 ➔ 10

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology

177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Peking Union Medical College Hospital | Trial completion date: Jun 2023 ➔ Dec 2024 | Trial primary completion date: Jun 2022 ➔ Oct 2024

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P1 trial • Oncology • Solid Tumor